MAP30 protein from Momordica charantia is therapeutic and has synergic activity with cisplatin against ovarian cancer in vivo by altering metabolism and inducing ferroptosis.

Chan, David W; Yung, Mingo Mh; Chan, Yau-Sang; Xuan, Yang; Yang, Huijuan; Xu, Dakang; Zhan, Jin-Biao; Chan, Karen Kl; Ng, Tzi-Bun; Ngan, Hextan Ys

Chan, David W; Yung, Mingo Mh; Chan, Yau-Sang; Xuan, Yang; Yang, Huijuan; Xu, Dakang; Zhan, Jin-Biao; Chan, Karen Kl; Ng, Tzi-Bun; Ngan, Hextan Ys.

Affiliation

Chan DW; Department of Obstetrics & Gynaecology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region. Electronic address: dwchan@hku.hk.
Yung MM; Department of Obstetrics & Gynaecology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region.
Chan YS; Department of Obstetrics & Gynaecology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region.
Xuan Y; Department of Obstetrics & Gynaecology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region.
Yang H; Department of Gynecological Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, 200032, PR China.
Xu D; Faculty of Medical Laboratory Science, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200030, PR China.
Zhan JB; Department of Biochemistry, Zhejiang University School of Medicine, 866 Yuhangtang Road, Zijingang Campus, Hangzhou, Zhejiang, 310058, PR China.
Chan KK; Department of Obstetrics & Gynaecology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region.
Ng TB; School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong Special Administrative Region.
Ngan HY; Department of Obstetrics & Gynaecology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region. Electronic address: hysngan@hku.hk.

Pharmacol Res ; 161: 105157, 2020 11.

Article in En | MEDLINE | ID: mdl-32814169

Subject(s)

Antineoplastic Agents, Phytogenic/pharmacology; Antineoplastic Combined Chemotherapy Protocols/pharmacology; Cisplatin/pharmacology; Energy Metabolism/drug effects; Ferroptosis/drug effects; Momordica charantia; Ovarian Neoplasms/drug therapy; Ribosome Inactivating Proteins, Type 2/pharmacology; AMP-Activated Protein Kinases/metabolism; Animals; Antineoplastic Agents, Phytogenic/isolation & purification; Cell Cycle Checkpoints/drug effects; Cell Line, Tumor; Cell Movement/drug effects; Cell Proliferation/drug effects; Drug Synergism; Female; Glycolysis/drug effects; Humans; Lipogenesis/drug effects; Mice, Inbred BALB C; Mice, Nude; Momordica charantia/chemistry; Neoplasm Invasiveness; Ovarian Neoplasms/metabolism; Ovarian Neoplasms/pathology; Ribosome Inactivating Proteins, Type 2/isolation & purification; Xenograft Model Antitumor Assays

Key words

A23187 (PubChem CID: 40486); AICAR (PubChem CID: 46780289); BODIPY (PubChem: CID: 25058173); Cisplatin (PubChem CID: 441203); Erastin (PubChem CID: 11214940); Ferrostatin 1 (PubChem CID: 4068248); MAP30; NaCl (PubChem CID: 5234); PVDF (PubChem CID: 3082294); Phenylmethylsulfonyl fluoride (PMSF) (PubChem CID: 4784); Propidium iodide (PI) (PubChem CID: 104981); STO-609 (PubChem CID: 3467590); Tris-HCl (PubChem CID: 93573); bitter melon; chemoresistance; ferroptosis; metabolism; ovarian cancer

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Traditional Medicines: Medicinas_tradicionales_de_asia / Medicina_china Main subject: Ovarian Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Cisplatin / Momordica charantia / Energy Metabolism / Ribosome Inactivating Proteins, Type 2 / Ferroptosis / Antineoplastic Agents, Phytogenic Type of study: Prognostic_studies Language: En Journal: Pharmacol Res Year: 2020 Type: Article

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google